FDA advisory panel considers Moderna's mRNA flu vaccine for older adults.
Photo: AP News
Health Added 45d ago 7 outlets

FDA advisory panel considers Moderna's mRNA flu vaccine for older adults.

An FDA advisory committee met to evaluate Moderna's mFlusiva, a flu vaccine using mRNA technology, for people aged 50 and older. A study of 40,000 people showed the vaccine reduced flu cases by about 27% compared to a standard-dose vaccine. The panel voted 9-0 to recommend approval.

3
Divergence score
7 outlets covered it, splitting into 6 framing camps across 3 bias groups.
6 camps
3 bias groups
Market signalBETA
The spectrum · how 7 outlets placed this story
LeftCenterRight
AP News
Washington Times
The Hill
NY Post
Reuters
Wall Street Journal
Jerusalem Post
Horizontal = outlet biasColor = this story's framing
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
The split, in one line
Coverage now splits three ways: regulatory milestone (wires citing unanimous vote), benefit-risk balance (financial press), and transformative technology narrative (international outlets framing mRNA era precedent), with Jerusalem Post emphasizing global innovation leadership over prior FDA tensions.
How each outlet covered it

Only the right is covering this

One side of the spectrum has stayed silent. That absence is itself a signal.

0
LEFT OUTLETS
0 of 7 outlets covering this story sit on that side of the spectrum.
0LEFT OUTLETS
THE RIGHT3 outlets · mostly neutral
First-of-its-kind flu vaccine could be coming as FDA panel weighs historic shot
NYP NY Post RIGHT
DOWN THE MIDDLE

“Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny” · AP News, The Hill, Reuters, Jerusalem Post

+Hide the full sourcingSee how all 7 outlets put it
5 tracked claims across 7 outlets
Fact ledger
All5Corroborated5
5/7
Corroborated
Moderna is seeking FDA approval for mFlusiva, an mRNA-based flu vaccine, for people aged 50 and older.
Corroborated
Disputed